Levomethadyl

31 interactions 1 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Octreotide Injection Mexiletine Mefloquine Foscarnet Injection Disopyramide Dolasetron Injection
14 Contraindicated 17 Major
All (31) Contraindicated (14) Major (17)

Major

Levomethadyl Acetazolamide Diamox® Sequels® Increased risk of QT prolongation Details Levomethadyl Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Levomethadyl Castor Oil Increased risk of QT prolongation Details Levomethadyl Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Levomethadyl Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Levomethadyl Furosemide Injection Disal Increased risk of QT prolongation Details Levomethadyl Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Ketoconazole Topical Extina® Foam Increased levomethadyl exposure Details Levomethadyl Lactulose Cholac® Increased risk of QT prolongation Details Levomethadyl Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Levomethadyl Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Levomethadyl Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Levomethadyl Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Levomethadyl Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Levomethadyl Mitapivat Aqvesme Reduced CYP3A substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.